Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd.

Key Points

• Global X Japan Co. Ltd. increased its stake in Regeneron by 354.5% in Q4, purchasing 3,261 shares to hold 4,181 shares worth about $3.23 million.
• Regeneron beat Q4 estimates with $11.44 EPS (vs. $10.74 est.) and $3.88 billion in revenue, and analysts have lifted price targets (average target ~$802.27) giving the stock a consensus "Moderate Buy" rating.
• Insiders sold 5,274 shares over the last three months (≈$4.14 million), leaving insiders with 7.02% ownership while institutional investors own 83.31% of the company.

Global X Japan Co. Ltd. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 354.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,181 shares of the biopharmaceutical company's stock after purchasing an additional 3,261 shares during the period. Global X Japan Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $3,227,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of REGN. CoreCap Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.2% in the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company's stock worth $134,000 after acquiring an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC increased its position in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company's stock worth $353,000 after purchasing an additional 21 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company's stock valued at $92,000 after buying an additional 21 shares during the period. MAI Capital Management lifted its position in Regeneron Pharmaceuticals by 2.1% during the third quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company's stock valued at $578,000 after buying an additional 21 shares in the last quarter. Finally, Independence Bank of Kentucky grew its stake in Regeneron Pharmaceuticals by 7.7% during the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company's stock worth $173,000 after buying an additional 22 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on REGN shares. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a "sector perform" rating in a research report on Monday, March 2nd. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an "overweight" rating in a research report on Monday, February 2nd. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an "outperform" rating in a report on Thursday, December 4th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Finally, Evercore increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $802.27.

Regeneron Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ:REGN opened at $756.73 on Friday. The stock has a market capitalization of $80.00 billion, a price-to-earnings ratio of 18.21, a PEG ratio of 2.01 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a 50 day moving average price of $764.58 and a 200 day moving average price of $704.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.07 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.